Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis

CAMBRIDGE, Mass. and TARRYTOWN, N.Y. , June 26, 2021 /PRNewswire/ — First-ever clinical data supporting safety and efficacy of in vivo   CRISPR genome editing in humans Interim readout in ongoing Phase 1 trial finds single 0.3 mg/kg dose of NTLA-2001 led to 87% mean reduction in serum TTR, with a


Get every new post delivered right to your inbox.

Original Source